This content is for healthcare professionals only.

This activity is funded by an independent medical education grant from Takeda Pharmaceuticals, U.S.A., Inc. This activity is jointly provided by USF Health and touchIME. This content is intended for healthcare professionals only. By selecting continue, you are confirming that you are a healthcare professional.

Faculty & Disclosures

Listen on the go
    • Faculty & Disclosures
    Dr Faith Davies

    NYU Langone Health, New York, NY, USA

    Dr Faith Davies is director of the Clinical Myeloma Program at the Perlmutter Cancer Center at NYU Langone Health in New York, NY, USA. read more

     

    Dr Davies’ research focus for over two decades has been on the biology and treatment of multiple myeloma, in particular the examination of potential new drugs and new genetic technologies. She is recognized internationally for her work looking at prognostic and predictive biomarkers (e.g. genetic abnormalities, imaging and minimal residual disease) within the context of clinical trials.

    Dr Davies is a member of the American Society of Hematology, the American Association for Cancer Research, the Royal College of Physicians (UK) and the Royal College of Pathologists (UK). She is widely published in leading peer-reviewed journals, including the New England Journal of Medicine, Lancet Oncology, Blood, Journal of Clinical Oncology and Leukemia.

    Dr Faith Davies discloses: Advisory board or panel fees from AbbVie, Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi and Takeda.
    Dr E Randolph Broun

    Oncology Hematology Care, Inc., Cincinnati, OH, USA

    Dr E Randolph ‘Randy’ Broun is a medical oncologist, haematologist and blood and marrow transplant (BMT) specialist with Oncology Hematology Care (OHC), Inc., Cincinnati, OH, USA. read more

    Dr Broun is highly experienced in the areas of BMT with alternative donors and BMT for germ cell cancer, and he is a member of the OHC team of experts who treat adult blood cancers with the ground-breaking chimeric antigen receptor T-cell therapy. He is also a principal investigator for OHC clinical trials on adult myeloid leukaemia, myelodysplastic syndromes and acute lymphoblastic leukaemia.

    Dr Broun is well known for his advocacy work and serves as a member of the Board of Directors of the Community Oncology Alliance, a non-profit organization dedicated to advocating for community oncology practices and, most importantly, the patients they serve. Dr Broun has contributed numerous editorials and spoken on issues such as House Bill 340B in an effort to make the cost of cancer fair for all providers and their patients.

    Dr E Randolph Broun discloses: Consultancy fees from Fresenius Kabi.
    Back to Faculty

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    Practice Aid
    CORRECT!
    Next question
    touchONCOLOGY touchONCOLOGY
    Now Playing:
    Up Next:
    Take CE/CME Test
    Start activity
     
    The value of real-world evidence in supporting clinical decision making
    Real-world evidence on the treatment of elderly/frail patients with multiple myeloma
    Managing elderly/frail patients with multiple myeloma in clinical practice
    Take CME Test
    Multiple Myeloma, Haematological Malignancies CE/CME accredited

    touchIN CONVERSATION
    A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation. Close

    How can real-world evidence guide the management of elderly and frail patients with multiple myeloma?

    Useful tips
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Explain the role and importance of real-world evidence (RWE) in supporting clinical decision making
    • Outline the key RWE related to the treatment of elderly and frail patients with multiple myeloma
    • Discuss the management of elderly and frail patients with multiple myeloma in clinical practice
    Overview

    In this activity, Dr Faith Davies, a multiple myeloma expert, and Dr E Randolph Broun, a community oncologist and haematologist, discuss some of the real-world evidence relating to the treatment of elderly and frail patients with multiple myeloma and how it influences their clinical practice. The discussion of these themes is based on questions posed by healthcare professionals involved in the care of patients with multiple myeloma.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    This activity has been designed to meet the educational needs of haematologists and oncologists involved in the management of multiple myeloma.

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty 

    Dr Faith Davies discloses: Advisory board or panel fees from AbbVie, Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi and Takeda.

    Dr E Randolph Broun discloses: Consultancy fees from Fresenius Kabi.

    Content reviewer

    Rebecca Margaret Gonzalez-Winegar, PharmD, BCOP has no financial interests/relationships or affiliations in relation to this activity.

    Touch Medical Director

    Hannah Fisher has no financial interests/relationships or affiliations in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu.

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Date of original release: 14 June 2022. Date credits expire: 14 June 2023.

    If you have any questions regarding credit please contact cpdsupport@usf.edu.

    This activity is CE/CME accredited

    To obtain the CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchCONGRESS

    Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Jorge Cortes: Ruxolitinib in myelofibrosis & rusfertide treatment in patients with phlebotomy-dependent polycythemia vera

    GO TO HUB

    touchPANEL DISCUSSION

    Improving outcomes in multiple myeloma with new treatment targets

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML

    GO TO HUB

    JOURNALS

    Myelodysplastic Syndromes – The Epigenetic Model for Drug Development?

    GO TO ARTICLE

    JOURNALS

    The Treatment of Chronic Myeloid Leukaemia (CML) in the Era of Tyrosine Kinase Inhibitors – What is New in the Battle of CML?

    GO TO ARTICLE

    Topics covered in this activity

    Multiple Myeloma/ Haematological Malignancies
    Register to touchONCOLOGY for FREE
    • Peer-reviewed journals and expert opinions
    • Interactive CME and e-learning modules
    • Video conference highlights
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from Takeda Pharmaceuticals, U.S.A., Inc.
    This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 14 June 2022. Date credits expire: 14 June 2023.

    This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

    Accept Decline
    Claim Credit
    touchIN CONVERSATION
    How can real-world evidence guide the management of elderly and frail patients with multiple myeloma?
    0.75 CE/CME credit
    Question 1/5
    You are considering entering your patient with multiple myeloma into a phase III clinical trial. Which of the following characteristics may preclude their entry into a clinical trial?

    Phase III randomized clinical trials may not be representative of the real-word multiple myeloma patient population. Patients with multiple myeloma of an advanced age, with rare molecular alterations, a poor performance status, those in a rural location or further from academic medical centres, and those with a high rate of comorbidities may be ineligible for phase III clinical trials.1,2 

    References

    1. Snyder JM, et al. Curr Oncol Rep. 2020;22:45.
    2. Terpos E, et al. Blood Cancer J. 2021;11:40.
    Question 2/5
    Which of the following is a strength of real-world evidence that can help guide the management of patients in clinical practice?

    Real-world evidence can better define the safety of a treatment, especially in terms of rare or long-term toxicities, as well as the tolerability in special patient populations, such as older patients.1

    Reference

    1. Di Maio M, et al. Oncologist. 2020;25:e746.
    Question 3/5
    Your patient is a 76-year-old female with newly diagnosed multiple myeloma. Which of the following should you use to assess the patient’s frailty?

    The IMWG Frailty Index is a multiple myeloma frailty assessment tool that incorporates age, the Katz Activity of Daily Living (ADL), the Lawton Instrumental Activities of Daily Living (IADL) and the Charlson Comorbidity Index (CCI). The index stratifies patients into three groups: fit, intermediate and frail, which can be used to predict mortality and the risk of toxicity with treatment.1 

    Abbreviation

    IMWG, International Myeloma Working Group.

    Reference

    1. Palumbo A, et al. Blood. 2015;125:2068–74.
    Question 4/5
    You have initiated triplet combination therapy in your 76-year-old frail female patient who has multiple myeloma. How might their frailty status affect your management of this patient while on the treatment regimen?

    Trials have shown that frail patients, as categorized by the IMWG Frailty Index, experience an increased incidence of grade ≥3 non-haematologic adverse events compared with patients categorized as fit or intermediate. These patients also have an increased risk of death, progression and treatment discontinuation regardless of ISS stage, chromosome abnormalities and type of treatment.1 Elderly symptomatic patients with multiple myeloma treated with novel agents should receive aggressive supportive care to improve their outcome.2

    Abbreviations

    IMWG, International Myeloma Working Group; ISS, International Staging System.

    References

    1. Palumbo A, et al. Blood. 2015;125:2068–74.
    2. Lee HC, et al. Blood Cancer J. 2021;11:134.
    Question 5/5
    According to real-world evidence, which of the following statements is true regarding risk of initiation of next line of therapy or death with proteasome inhibitor triplet therapy in intermediate/frail patients with relapsed/refractory multiple myeloma?

    A retrospective, US population-representative EHR study of patients with relapsed/refractory multiple myeloma demonstrated that risk of initiation of next line of therapy or death was lower with ixazomib triplet therapy vs carfilzomib triplet therapy (HR 0.70; P=0.04) and higher with carfilzomib triplet therapy vs bortezomib triplet therapy (HR 1.38, p=0.05) among patients with a modified frailty score of intermediate to frail.1   

    Abbreviations

    EHR, electronic health record, HR, hazard ratio.

    Reference

    1. Chari A, et al. Expert Rev Hematol. 2020;13:421–33.
    Back to Activity

    You may also be interested in...

    touchTALKS

    What’s on the horizon for higher-risk MDS? An update on emerging novel agents

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Jorge Cortes, EHA 2022: Updates from the QuANTUM-First trial of quizartinib versus placebo plus intensive chemotherapy in FLT3-ITD+ AML

    GO TO HUB

    touchEXPERT OPINIONS

    Optimizing care with CAR T-cell therapy now and in the future for patients with B-cell malignancies

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Massimo Breccia, ASH 2019: Discontinuing Tyrosine-kinase Inhibitors in patients with Chronic Myeloid Leukemia

    GO TO HUB

    JOURNALS

    Monoclonal Antibodies for the Treatment of Multiple Myeloma— A New Paradigm

    GO TO ARTICLE

    JOURNALS

    Stem Cells in Acute Lymphoblastic Leukaemia

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from Takeda Pharmaceuticals, U.S.A., Inc.
    This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 14 June 2022. Date credits expire: 14 June 2023.

    Faculty
    Podcast
    Featured
    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72